1. Immune Pharma
Targeted Medicine
Immune Pharmaceuticals Corporation
Developing the Next Generation Monoclonal Antibody Therapeutics
New York Biotechnology Association
Corporate Showcase
April 19, 2010

2. Immune Pharma A Development Stage Monoclonal Antibody Company
Targeted Medicine
IMMUNE Pharmaceuticals is a New York based biopharmaceutical
company focused on First-in-Class Therapeutics addressing significant
unmet medical needs in Oncology, Immunology and Infectious
Diseases.
IMMUNE is building a portfolio of Clinical and Pre-Clinical MAbs with
multiple shots on goal for $ 1 billion drugs based on novel targets and
proprietary best in class antibody technologies.
IMMUNE is establishing a Research Center in Israel to capitalize on its
academic relationships with Weizmann Institute and Hebrew University.

3. Immune Pharma Investing in a MAbs company is highly attractive
Targeted Medicine
1. Large and Growing Market
 Monoclonal Antibody Market $ 40 B in 2009 to reach $ 60 B by 2014
 5 of top 10 drugs are MAbs and 8 have already reached $ 1 B in sales
2. Higher Development Success Rate
 50% higher success rate with MAbs compared to small molecules (Tufts CSDD)
 Faster clinical development and regulatory review ( IND to BLA in 6years)
3. Longer Commercial exclusivity with reduced Generic Threats
 US Healthcare Law provides for at least 12 Years Marketing Exclusivity
 Antibody Complexity and lack of Regulatory consensus to delay Biosimilars
4. Improved Engineering and Decreasing Manufacturing Costs
 Novel Antibody Engineering delivers improved performance
 Manufacturing Costs have decreased 50% in the last 10 years
5. Rich Partnering Opportunities
Partnering for innovative phase 2 MAb exceeds $ 500 M per deal value
6. Higher Market and M&A Exit Valuations
 Many company valuations range from $ 500 M to $ 2+ B

4. Immune Pharma A Portfolio with multiple shots on goal for $ 1 B drugs
Targeted Medicine
.
 Multiple value creating milestones in next 3 years:
1. First-in Class Highly Specific Rheumatoid Arthritis MAb to reach
phase II a ready for Corporate Partnering
2. In Licensed MAb for orphan indication to progress to phase II/ III
3. Two INDs for novel MAbs
4. Three MAbs promoted to Early Development Candidates ( pre-clinical POC)
5. Validated Fully Human and Bi-Specific Antibody technology platforms

5. Immune Pharma
Targeted Medicine
Beyond TNFalpha inhibitors
The first highly specific MAb for Rheumatoid Arthritis
IN PARTNERSHIP WITH

6. Immune Pharma Significant Unmet Medical Need
Targeted Medicine for new Rheumatoid Arthritis Treatment
 Only 30% of Rheumatoid Arthritis (RA) patients are treated with TNF-alpha
blockers (Enbrel $8B, Remicade $6.9B, Humira $ 5.5B)
1. Unspecific immuno-suppression is responsible for severe and
occasionally lethal infections, including Tuberculosis,
2. 2/3 of treated patients have Partial Response with TNF-alpha Blockers
and still experience daily pain, stiffness and fatigue
3. 25-40% patients do not respond to TNF-apha blockers even at the lowest
efficacy level (ACR 20)
4. 20% of patients experience diminishing response with TNF-alpha
blockers over the course of the first year
High Unmet Medical Need for a Highly Specific RA treatment
with improved efficacy and limited off target safety concerns

7. Immune Pharma First in Class CD44vRA MAb
Targeted Medicine Highly Specific for Rheumatoid Arthritis
 CD44vRA MAb recognizes and targets
specific protein expressed on the
surface of pathological inflammatory
cells but not expressed on normal cells,
so healthy cells remain undamaged:
 RA Specific: binds to 75% of synovial
fluid cells from RA patients,
Site of  Target Selective: not active in
action
 Peripheral white blood cells from
of anti
hCD44vRA
the same patients,
MAb  Keratinocytes from normal donors,
 Synovial fluid cells from
osteoarthritis patients
Golan, Naor & all, Journal of Autoimmunity vol 28
issue 2-3 March-May 2007, Pages 99-113

8. Immune Pharma CD44vRA MAb binds to Gal-8
Targeted Medicine and induces Apoptosis of Inflammatory Synovial Cells
The involvement of CD44 and its novel ligand Galectin-8 in the regulation of Auto-Immune Inflammation
Golan, Naor & all, J.Immunol. 2007;179;1225-1235

9. Immune Pharma CD44vRA MAb equal or better than
Targeted Medicine anti-TNFalpha in Ex Vivo and In Vivo models
 Proof of Concept studies in
Collagen Induced Arthritis
standard In Vivo model
 Histo-pathology shows:
– Reduction in cell inflammation
– Reduction in fibro-vascular
proliferatiion
– Reduction in cartilage
destruction and improved repair
 Anti-Human CD44vRA MAb
2.9
Negative Control
F8:33 200 ug
induces resistance to Collagen
2.7
F8:33 Time 200 ug
F8:33 70 ug induces Arthritis in DBA/1 mouse
2.5
anti-TNF
model because of the homology
between mouse CD44 v4/v5 and
Paw (mm)
2.3
2.1
human CD44vRA

1.9
Confirms ex vivo apoptotic
1.7
activity of inflammatory synovial
1.5
1 2 3 4 5 6 7 cells from RA patients
Days

10. Immune Pharma Attractive Target Product Profile
Targeted Medicine for First in Class Anti-Human CD44vRA MAb
Anti-Human Anti-TNFalpha Oral
CD44vRA MAb MAb Kinase Inhibitor
Selectivity High Average Average
Non specific
immunosuppression Low Moderate to High Moderate to High
Risk of severe
infections and TB
Risk of High Blood No No Yes
Pressure
Treatment
Responders > 75% 50% 60%
(ACR 20) up to 100% in
CD44vRA positive
patients
Biomarker for Yes No No
responders

11. Immune Pharma
Targeted Medicine
Targeting Cancer Stem Cells
with Fully Human Antibodies (cellular engineering)

12. Immune Pharma Treatment of cancer stem cells
Targeted Medicine one step towards the cure*
1. Next paradigm in cancer treatment
2. Significant data published and
acknowledged
3. Cancer stem cells resist current
treatments
4. Cancer stem cells lead to relapsing
cancer
5. Targeted therapeutics of cancer
stem cells can lead to full cancer
cure
*According to the American Society of Clinical Oncology,
Journal of Clinical Oncology, June 2008

13. Immune Pharma First in Class Anti-CD44 MAb
Targeted Medicine targeting Cancer Stem Cells
1. IMP 111 is a novel Anti-CD44 MAb
with the following activity:
 Targets specific epitope on
constant part of CD44 on AML
cells,
 Survival benefit in knock out
mice grafted with human
leukemia cells
 No hemagglutination
2. Antibody Dependant Cellular
Phagocytosis (ADCP) is a novel
mechanism of action demonstrated
with IMP-111
3. Follow on screening of CD44 variant
targets specific to Stem Cells in
various malignancies and
development of a library of fully
human antibodies

14. Immune Pharma IMPH Novel “Fully Human” MAbs
Targeted Medicine Initial application for anti CD44 MAbs in AML
A Cellular Engineering Approach
Human Lymphoma B Cells
+
Human Cord Blood Mouse Myeloma Cells
Sorting
CD34+ sorted cells
Transplant
Hetero-Myeloma
Selected
Antigen +
Fusion
Human Hybridomas
Spleen
extraction
Mouse with human
immune system
Splenocytes
Fully Human MAbs
14

15. Immune Pharma
Targeted Medicine
Bi-specific Antibodies
Enhanced Targeted Efficacy against Hematological and Solid Tumors

16. Immune Pharma
Targeted Medicine
Developing three novel Bi-Specific MAbs approaches
1. Quadrivalent bi-specific antibodies
• 3 Year EC financed pan-European academic research coordinated by
IMPH co-founder
• Patent License from CNRS-France
2. Bi-Specific Immuno-NanoParticules
• Scientific collaboration between IMPH co-founder and Hebrew
University (Prof. Benita)
• One or two antibodies grafted on a NanoParticule
• Ability to co-deliver a chemotherapeutic
• Patent License from Yissum-Hebrew University
3. Dual Soluble Receptor Fusion Protein
• Developed by IMPH

17. Immune Pharma IMPH to develop bi-specific anti-ErbB/ HER2
Targeted Medicine antibodies in partnership with Weizmann Institute
Combinations of two anti-ErbB antibodies targeting different epitopes
may increase therapeutic efficacy through enhanced endocytosis
Synergistic Tumor Inhibition by anti-HER2
Antibody combinations
T. Ben-Kasus, Bilha Schechter, Yossi Yarden &
Michael Sela, Weizmann Institute ,of Science
Publication in Proceedings of National Academy
of Sciences, March 2009

18. Immune Pharma R&D Investments supported
Targeted Medicine by strong Intellectual Property
 Exclusive worldwide license from Maimonidex -Yissum/ Hebrew University Patents
on CD44vRA
 Patents filed by IMPH for CD44 target and antibody against Leukemia Stem Cells
 Patents filed by IMPH on Fully Human Antibodies (Cellular Engineering)
 Option to exclusive license from Weizmann Institute on HER2 combinations
 Option to exclusive license from Feinstein Institute on CLL targets
 Option to exclusive license on Quadrivalent Bi-Specific Antibodies from European
Academic Consortium
 Option to license on ImmunoNanoParticules from Yissum-Hebrew University

19. Immune Pharma IMPH Academic and Industry Network
Targeted Medicine generates a Pipeline of Opportunities
 IMPH Management has extensive global relationships with leading Academic
Institutions and with Bio-Pharmaceutical companies, creating opportunities for
rewarding partnerships such as:
1. In licensing or co-development opportunity of First-in-class novel anti-
angiogenic target and antibody for the treatment of Age-Related Macular
Degeneration
2. Development of Bi-Specific Antibodies against Specific targets in Chronic
Lymphocytic Leukemia ( Collaboration with Prof. Nick Chiorazzi-
Feinstein Institute-New York)
3. Development of Antibodies and Novel Delivery forms against anti-
infective targets (Collaboration with Professor Pothier- France)
4. Development of MAbs against specific novel targets for a mid-size
Biotech company

20. Immune Pharma
Targeted Medicine A Strong Management Team
 Daniel Teper, PharmD, MBA, Chief Executive Officer and Co-founder
Dr Teper has been a Partner at Strategy Consulting firms, ISO Healthcare (now part of Monitor),
Bionest , and 21 West, advising leading pharma and biotech companies. He has previously held
sales, marketing, new product development and general management positions at Novartis, GSK,
Sanofi-Aventis. Daniel holds an MBA from INSEAD and a Doctor of Pharmacy (PharmD) degree.
 J.E. Kadouche, PhD, Co-founder, President and Chief Scientific Officer
Dr Kadouche has 25 years experience in the development of MAbs in both Academia and Industry.
He was until recently the CEO of MAT an Antibody company where he built and partnered a clinical
and pre-clinical portfolio. He is the founder of Clonatec and was an advisor to Sangstat, Roche, Merck
AG and J&J. He holds PhD in Immunology from the Pasteur Institute and was an Assistant Professor
at St Louis Hospital.
 John Mohr, CPA, Chief Financial Officer and Chief Business Officer
Mr Mohr is a seasoned Business Development executive with over 20 years industry experience. He
was until recently the SVP, Business Development at CV Therapeutics which was acquired by Gilead
for $ 1.4 billion. As President of Fournier USA, he partnered with Abbott and launched Tricor, now a
$1 billion drug. John is a CPA and started his career in Finance at Merck & Co..
 Mitchell Glass, MD, Senior Vice President, Chief Medical Officer
Dr. Glass brings leadership experience in drug development at GSK and AstraZeneca as well as
emerging Biotech companies and Academia. Mitchell is strong relationships with the FDA and the
NIH. received his MD from the University of Chicago and is a member of the American Thoracic
Society and American Academy of Asthma, Allergy & Immunology.
 Eli Eldan, MBA, Vice-President, General Manager, Israel Operations

21. Immune Pharma IMMUNE aims to deliver Multiple Value Creating
Targeted Medicine Milestones over the next 3 years
2011 2012 2013
First In Class RA MAb
Phase I Phase II
In Licensed Orphan MAb
Phase I Phase II
INDs Novel MAbs
Early Dev. Candidates
Antibody Technology
Platform Partnering

22. Immune Pharma
Targeted Medicine Contact Details
Daniel Teper
CEO
Email: d.teper@immunepharma.com
Jean Kadouche
President, Research
Email: j.kadouche@immunepharma.com
22